{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T21:54:02Z","timestamp":1766267642884,"version":"3.37.3"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["VI-D&P\/552\/2016\u201317\/TDT(G)"],"award-info":[{"award-number":["VI-D&P\/552\/2016\u201317\/TDT(G)"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Indian Pharmaceutical Association","award":["VI-D&P\/552\/2016\u201317\/TDT(G)"],"award-info":[{"award-number":["VI-D&P\/552\/2016\u201317\/TDT(G)"]}]},{"DOI":"10.13039\/100008901","name":"College of Pharmacy","doi-asserted-by":"publisher","award":["VI-D&P\/552\/2016\u201317\/TDT(G)"],"award-info":[{"award-number":["VI-D&P\/552\/2016\u201317\/TDT(G)"]}],"id":[{"id":"10.13039\/100008901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Analytical Chemistry"],"published-print":{"date-parts":[[2021,5,11]]},"abstract":"<jats:p>Neostigmine methylsulfate is an anticholinesterase agent and is clinically used for treating myasthenia gravis. It is also used for reversing nondepolarising neuromuscular blocking agents. Neostigmine methylsulfate may be administered by intravenous, intramuscular, or subcutaneous injection. In this research paper, a distinct stability-indicating reverse phase HPLC method was developed and validated for the quantitative determination of related impurities and degradation impurities in neostigmine methylsulfate API and injection formulation. The specific objective was to improve the resolution between European Pharmacopoeia listed impurity A and impurity B and degradation impurity of neostigmine methylsulfate API and injection formulation. The analysis was performed using Kromasil C18 column at 30\u00b0C of column oven temperature with phosphate-buffer\/acetonitrile in a gradient mode. The RP-HPLC method was developed and validated for in-house neostigmine methylsulfate synthesis process sample and injection formulation. The injection formulation sample was studied for accelerated stability, temperature cycling stability, and photostability. The validation studies for neostigmine methylsulfate synthesis process API were studied using impurity A, impurity B, and impurity C. The analytical method validation parameters studied were specificity, precision, linearity, limit of detection, limit of quantitation, accuracy, and robustness. The API and the injection formulation were subjected to forced degradation under acid, alkali, oxidation, and photolytic and thermal conditions. The proposed method showed a significantly improved RRT (Relative Retention Time) of impurity A and impurity B with a resolution greater than 1.5. The developed method eliminates the use of an ion-pairing agent and thereby a good performance of column was established.<\/jats:p>","DOI":"10.1155\/2021\/5570173","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T18:35:39Z","timestamp":1620844539000},"page":"1-14","source":"Crossref","is-referenced-by-count":3,"title":["A RP-HPLC Method for the Analysis of Neostigmine Methylsulfate and Process-Related Impurities, Forced Degradation Studies, in the Injection Formulation"],"prefix":"10.1155","volume":"2021","author":[{"given":"Manali","family":"Parab","sequence":"first","affiliation":[{"name":"Bombay College of Pharmacy (Autonomous), Kalina, Santacruz East, Mumbai 400098, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7198","authenticated-orcid":true,"given":"Vaishali A.","family":"Shirsat","sequence":"additional","affiliation":[{"name":"Bombay College of Pharmacy (Autonomous), Kalina, Santacruz East, Mumbai 400098, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogita M.","family":"Kodgule","sequence":"additional","affiliation":[{"name":"IQGEN-X Pharma Pvt. Ltd., A-165, Khairane Road, Sector 2, Kopar Khairane, Navi Mumbai 400710, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandar","family":"Kodgule","sequence":"additional","affiliation":[{"name":"IQGEN-X Pharma Pvt. Ltd., A-165, Khairane Road, Sector 2, Kopar Khairane, Navi Mumbai 400710, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","article-title":"Forced degradation to develop stability-Indicating methods","author":"R. Simon","year":"2012","journal-title":"Pharmaceutical Outsourcing"},{"issue":"5","key":"2","first-page":"238","article-title":"Forced degradation studies for drug substances and drug products- scientific and regulatory considerations","volume":"7","author":"T. Rawat","year":"2015","journal-title":"Journal of Pharmaceutical Science and Research"},{"issue":"2","key":"3","first-page":"137","article-title":"Forced degradation studies: regulatory guidance, characterization of drugs, and their degradation products\u2014a review","volume":"10","author":"S. Venkataraman","year":"2018","journal-title":"Drug Invention Today"},{"issue":"5","key":"4","first-page":"86","article-title":"An introduction to the accelerated stability assessment program","volume":"20","author":"C. Rack","year":"2017","journal-title":"American Pharmaceutical Review"},{"article-title":"Stability Testing of Pharmaceuticals, Series Title-Methods in Pharmacology and Toxicology","year":"2018","author":"S. Bajaj","key":"5"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.09.041"},{"issue":"4","key":"7","first-page":"184","article-title":"Stability studies: a review","volume":"1","author":"A. Arunachalam","year":"2013","journal-title":"Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-9140(96)02179-0"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2006.05.012"},{"volume-title":"Impurities in New Drug Substance","year":"2006","author":"ICH Q3A (R2)","key":"10"},{"volume-title":"Impurities in New Drug Products","year":"2006","author":"ICH Q3B (R2)","key":"11"},{"volume-title":"Guideline for Residual Solvents","year":"2018","author":"ICH Q3C (R7)","key":"12"},{"volume-title":"Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use","year":"2011","author":"ICH S2 (R1)","key":"13"},{"volume-title":"BLOXIVERZ\u2122 (Neostigmine Methylsulfate Injection)","year":"2013","author":"Food and Drug Administration","key":"14"},{"key":"15","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-801238-3.97314-8","article-title":"Neostigmine","volume-title":"Reference Module in Biomedical Sciences","author":"J. Liu","year":"2017"},{"issue":"10","key":"16","first-page":"1264","article-title":"Study on RP-HPLC content determination of neostigmine methylsulfate for injection","volume":"25","author":"C.-I. Yue","year":"2005","journal-title":"Chinese Journal of Pharmaceutical Analysis"},{"author":"P. Peddi","key":"17","article-title":"Development and validation of stability indicating HPLC method for estimation of related substances in neostigmine"},{"issue":"12","key":"18","first-page":"1236","article-title":"Development and validation of stability indicating RP- HPLC method for the estimation of glycopyrrolate and neostigmine in bulk and tablet","volume":"7","author":"K. Jogi","year":"2016","journal-title":"International Journal of Scientific & Engineering Research"},{"key":"19"},{"key":"20","doi-asserted-by":"crossref","DOI":"10.1002\/9781118592014","volume-title":"Practical HPLC Method Development","author":"L. R. Snyder","year":"1997","edition":"2nd"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2006.01.047"},{"volume-title":"Gradient Elution Chromatography, Encyclopedia of Analytical Chemistry","year":"2006","author":"J. W. Dolan","key":"22"},{"key":"23","first-page":"406","article-title":"How fast can a gradient be run","volume":"24","author":"J. W. Dolan","year":"2011","journal-title":"LC\/GC Europe"},{"volume-title":"Stability Testing of New Drug Substances and Products","year":"2003","author":"ICH Q1A (R2)","key":"24"},{"volume-title":"Stability Testing: Photostability Testing of New Drug Substances and Products","year":"1996","author":"ICH Q1B","key":"25"},{"volume-title":"Evaluation of Stability Data","year":"2003","author":"ICH Q1E","key":"26"},{"volume-title":"Validation of Analytical Procedures: Text and Methodology","year":"2005","author":"ICH Q2 (R1)","key":"27"}],"container-title":["International Journal of Analytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijac\/2021\/5570173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijac\/2021\/5570173.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijac\/2021\/5570173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T18:36:07Z","timestamp":1620844567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ijac\/2021\/5570173\/"}},"subtitle":[],"editor":[{"given":"Victoria F.","family":"Samanidou","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":27,"alternative-id":["5570173","5570173"],"URL":"https:\/\/doi.org\/10.1155\/2021\/5570173","relation":{},"ISSN":["1687-8779","1687-8760"],"issn-type":[{"type":"electronic","value":"1687-8779"},{"type":"print","value":"1687-8760"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}